Post Myocardial Infarction Heart Failure Therapeutics
1. Inspra patent expiration
Treatment: Treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial infarction; Use of eplerenone in combination with an angiotensi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6863902 | UPJOHN | Immediate release eplerenone compositions |
Apr, 2020
(5 years ago) | |
|
US6558707 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6747020 (Pediatric) | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May, 2020
(5 years ago) | |
|
US7157101 (Pediatric) | UPJOHN | Micronized eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6495165 (Pediatric) | UPJOHN | Eplerenone compositions having improved bioavailability |
Jun, 2020
(5 years ago) | |
|
US6410524 (Pediatric) | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May, 2020
(5 years ago) | |
|
US6410054 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6534093 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6863902 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Oct, 2020
(5 years ago) | |
| US6410524 | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov, 2019
(6 years ago) | |
| US6410054 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6747020 | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov, 2019
(6 years ago) | |
| US6534093 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US7157101 | UPJOHN | Micronized eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6495165 | UPJOHN | Eplerenone compositions having improved bioavailability |
Dec, 2019
(6 years ago) | |
| US6558707 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jul 31, 2011 |
Drugs and Companies using EPLERENONE ingredient
Market Authorisation Date: 27 September, 2002
Dosage: TABLET
How can I launch a generic of INSPRA before it's drug patent expiration?
More Information on Dosage
INSPRA family patents
